NCT04846179CompletedPhase 4
To Evaluate the Effect of Ginkgo Biloba Extract on Optic Nerve Head Perfusion Examined Using OCTA
To Evaluate the Effect of Ginkgo Biloba Extract on Optic Nerve Head Perfusion
Source: ClinicalTrials.gov · Last updated 21 Aug 2024
Brief summary (registry, in English)
Glaucoma is defined as progressive neuropathy of the optic nerve. It is an important cause of irreversible blindness worldwide. Lowering the intraocular pressure is the only proven treatment for this neurodegenerative disease. However, there is ongoing research looking at another modifiable risk factor that affects the development and progression of this disease. Ginkgo biloba (Ginkgoacease) is a tree species that has been used in traditional medicine for several hundred years to treat various diseases include improving vascular perfusion. We propose a study examining the effect of Ginkgo biloba extract supplementation on ocular perfusion using optical coherence tomography angiography.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 12 Apr 2021
- Start date
- 1 May 2021
- Primary completion date
- 31 Mar 2024
- Lead sponsor
- Nova Scotia Health Authority
- Diseases
- Glaucoma
- NCT number
- NCT04846179
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 15
- From 1 May 2021 to the primary completion date, 31 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Those taking anticoagulant therapy
- Patients with a history of seizures or who were currently taking anti-convulsant medication, and
- Taking any drugs that may interact with GBE
Other illness
- History of ocular disease affecting ocular perfusion (e.g. CRAO, CRVO, diabetic retinopathy, ocular ischemic syndrome, ischemic optic neuropathy)
- History of glaucoma surgery
- Those with blood disorders or diabetes
Age
- Younger than 18 years of age
Other
- Angle closure glaucoma or secondary open angle glaucoma
- Refraction exceeding 6D spherical equivalent or 3D astigmatism
- Severe corneal, lens, vitreous media opacity limit signal strength of OCTA imaging
- Severe open angle glaucoma with visual field mean deviation worse than -10dB
- Inability to comply to treatment intervention (e.g. swallowing difficulty)
- Women who were pregnant, planning to become pregnant, or who were breast-feeding,
Who the study is looking for
- 18 years of age or older
- Early open angle glaucoma based on gonioscopy, clinical assessment of optic nerve head, OCT optic nerve and Humphrey Visual Field 24-2 (MD \< -10dB) and positive Glaucoma Hemifield Test
- BCVA equal or better than 6/12
- Written consent
- Ability to comply with treatment intervention for duration of study
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nova Scotia Health Coordinator of this site? Confirm its status | Halifax | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.